Piatnitskaia, Svetlana,
Rafikova, Guzel,
Bilyalov, Azat,
Chugunov, Svyatoslav,
Akhatov, Iskander,
Pavlov, Valentin,
Kzhyshkowska, Julia (2024) with the
immune system throughout the entire duration of implant use. The acute as well as long-term decisions
Objective - The aim of the work was to study the contribution of the
immune response mediator genes
of conventional therapies needs to consider cancer-specific and patient-specific programming of innate
immunity of activating the
immune response against tumor
cells. Clinically used checkpoint inhibition using antibodies
MENG, X.,
DUAN, C.,
PANG, H.,
CHEN, Q.,
HAN, B.,
MAGAFUROV, D.A.,
WU, P.,
LI, Z.,
ZHAO, S.,
WANG, R.,
LIN, L.,
JIANG, C.,
CAI, J.,
ZHA, C. (2019) . Gliomas with DDR alterations exhibit distinct
immune phenotypes, and
immune cell types and cytokine